Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2023 Jan;55(1):134-140.
doi: 10.1007/s11239-022-02720-7. Epub 2022 Nov 8.

Time from blood draw to multiple electrode aggregometry and association with platelet reactivity

David Hesselbarth #  1 , Diona Gjermeni #  1 , Sofia Szabo  1 , Patrick M Siegel  1 , Philipp Diehl  1   2 , Martin Moser  1 , Christoph Bode  1 , Christoph B Olivier  3
Affiliations
Observational Study

Time from blood draw to multiple electrode aggregometry and association with platelet reactivity

David Hesselbarth et al. J Thromb Thrombolysis. 2023 Jan.

Abstract

Results from multiple electrode aggregometry (MEA) may vary according to pre-analytic factors. This study aimed to analyze the association of time from blood draw to MEA in patients undergoing percutaneous coronary intervention (PCI). In this observational single-center cohort study, platelet aggregation (aggregation units, U) was quantified by MEA (Multiplate Analyzer) after stimulation with adenosine diphosphate (ADP; final concentration [Fc] 6.4 μM), thrombin receptor activating peptide (TRAP; Fc 32 μM), or arachidonic acid (AA; Fc 0.5 mM) in patients treated with ASA and clopidogrel following PCI. High on-clopidogrel platelet reactivity (HPR) was defined as ADP-induced platelet aggregation ≥ 46 U. The manufacturer recommends performing the analysis within 30-180 min after blood draw. Patients were grouped according to the time from blood draw to MEA: 30-180 min, < 30 min, or > 180 min. Platelet function of 273 patients with coronary artery disease undergoing PCI with dual antiplatelet therapy was analyzed. The median age was 72 years (interquartile range, IQR 62-79) and 179 (66%) were male. Median ADP-, TRAP-, and AA-induced aggregation was 25 (IQR 18-36) U, 79 (IQR 63-96) U, and 12 (IQR 7-18) U, respectively. For those analyzed within 30-180 min from blood draw, no significant correlation of time from blood draw to MEA was observed 1) ADP (r = - 0.04, p = 0.51); 2) TRAP (r = - 0.06, p = 0.32); 3) AA (r = - 0.03, p = 0.67). In patients undergoing percutaneous coronary intervention and treated with dual antiplatelet therapy, the time from blood draw to multiple electrode aggregometry does not correlate with ADP- induced aggregation when the measurement occurred within the recommended time interval of 30-180 min after blood draw.

Keywords: Antithrombotic therapy; Coronary syndrome; Multiple electrode aggregometry; Platelet reactivity.

PubMed Disclaimer

Conflict of interest statement

No potential competing interest was reported by the authors.

Figures

Fig. 1
Fig. 1
Multiple electrode aggregometry performed within the manufacturers’ recommendations (30–180 min) demonstrated no relevant correlation from time to blood draw to MEA with ADP-, TRAP-, AA-induced aggregation and r-ADP aggregation (A–D)
Fig. 2
Fig. 2
Median ADP- TRAP-, induced aggregation and median r-ADP aggregation (A, B, D) were not significantly different when performed outside the manufacturers’ recommended timeframe (30–180 min) to MEA measurement. AA-induced aggregation when measured > 180 min was significantly increased (C)
See this image and copyright information in PMC

References

    1. Olivier C, Diehl P, Schnabel K, Weik P, Zhou Q, Bode C, Moser M. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry. Thromb Haemost. 2014;111:266–272. doi: 10.1160/TH13-06-0508. - DOI - PubMed
    1. Thiele H, Barbato E, Barthelemy O, Bauersachs J, Bhatt DL. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2020;42:1289. - PubMed
    1. Fei Y, Lam CK, Cheung BMY. Efficacy and safety of newer P2Y12 inhibitors for acute coronary syndrome: a network meta-analysis. Sci Rep. 2020;10:16794. doi: 10.1038/s41598-020-73871-x. - DOI - PMC - PubMed
    1. Zhang Y-J, Li M-P, Tang J, Chen X-P. Pharmacokinetic and pharmacodynamic responses to clopidogrel: evidences and perspectives. Int J Environ Res Public Health. 2017;14:301. doi: 10.3390/ijerph14030301. - DOI - PMC - PubMed
    1. Sibbing D, Aradi D, Jacobshagen C, Gross L, Trenk D, Geisler T, Orban M, Hadamitzky M, Merkely B, Kiss RG, Komócsi A, Dézsi CA, Holdt L, Felix SB, Parma R, Klopotowski M, Schwinger RHG, Rieber J, Huber K, Neumann F-J, Koltowski L, Mehilli J, Huczek Z, Massberg S, Parma R, Parma Z, Lesiak M, Komosa A, Huczek Z, Koltowski L, Kowara M, Rymuza B, Klopotowski M, Malek L, Aradi D, Veress G, Dézsi AD, Merkely B, Lux Á, Kiss RG, Papp J, Kovács A, Dézsi CA, Amer S, Ruzsa Z, Róna S, Komócsi A, Ili R, Ungi I, Nagy F, Zweiker R, Tóth-Gayor G, Huber K, Haller P, von Scheidt W, Blüthgen A, Neumann F-J, Trenk D, Leggewie S, Kreider-Stempfle HU, Remp T, Kara K, Mügge A, Wutzler A, Fichtlscherer S, Zeiher AM, Seeger F, Hinterseer M, König A, Lederle S, Jacobshagen C, Czepluch F, Maier L, Schillinger W, Sossalla S, Hummel A, Felix S, Karakas M, Sydow K, Rudolph T, Halbach M, Gori T, Münzel T, May A, Gerstenberg C-M, Pilecky D, Rieber J, Deichstetter M, Sibbing D, Mehilli J, Gross L, Kääb S, Löw A, Orban M, Orban M, Sattler S, Deuschl S, Teupser D, et al. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. The Lancet. 2017;390:1747–1757. doi: 10.1016/S0140-6736(17)32155-4. - DOI - PubMed

Publication types